TIMP-1特异性小干扰RNA真核表达载体转染肝星状细胞效率的检测

目的 提高TIMP-1小干扰RNA真核表达载体pGCsi-U6/TIMP-1 shRNA在大鼠肝星状细胞HSC-T6中的转染效率.方法 构建携带绿色荧光蛋白(GFP)基因的小干扰RNA真核表达载体pGCsi-U6/TIMP-1 shRNA,采用阳离子脂质体介导法将pGCsi-U6/TIMP-1 shRNA质粒转染入HSC-T6细胞,实验根据质粒DNA和阳离子脂质体LipofectamineTM 2000的不同比例分为5组:2 μg/0μL、2 μg/4 μL、2 μg/6 μL、2 μg/8 μL、2 μg/10 μL,同时设空白对照组.转染48 h后,应用激光共聚焦显微镜观察各组转染情况,同时用流式细胞仪计算转染效率.结果 激光共聚焦显微镜观察和流式细胞仪检测均说明质粒与脂质体比例为2 μg/8 μL组转染效率显著高于其余各比例组,差异具有统计学意义.转染效率与脂质体和质粒的比例有关.结论 按照合适的质粒和脂质体比例,质粒pGCsi-U6/TIMP-1 shRNA转染HSC-T6可达较高转染效率,是转染HSC-T6较为理想的瞬时表达载体.     

肝纤维化相关细胞因子双重RNA干扰质粒的构建及转染肝星状细胞研究

目的构建以大鼠CTGF和TIMP-1基因为靶点的双重RNA干扰表达载体质粒,以检测其转染肝星状细胞的效率.方法筛选出对CTGF和TIMP-1基因最有效的RNA干扰靶位,各设计1对含有短发夹结构的RNA 干扰靶点序列,分别克隆到质粒载体psiRNA-DUO-GFPzeo,构建含目的靶基因片段的重组质粒载体psiRNA-GFP-CT-GF、psiRNA-GFP-TIMP-1和psiRNA-GFP-Com（含有CTGF和TIMP-1）,进行酶切和测序鉴定.将构建成功的重组质粒psiRNA-GFP-CTGF、psiRNA-GFP-TIMP-1和psiRNA-GFP-Com转染大鼠肝星状细胞,在荧光显微镜下观察质粒转染情况,用流式细胞仪检测转染效率.结果酶切与测序结果提示重组质粒 psiRNA-GFP-CTGF、psiR-NA-GFP-TIMP-1和psiRNA-GFP-Com成功构建;成功将重组质粒psiRNA-GFP-CTGF、psiRNA-GFP-TIMP-1和psiRNA-GFP-Com转染肝星状细胞,在24小时,空质粒组、CTGF组、TIMP-1组和CTGF ＋TIMP-1组转染效率分别为15±2%、13±1%、15±1%和14±2%,均低于质粒psiRNA-GFP-Com转染组（Com组,20±2%,P〈0.05）;在48小时,空质粒组、CTGF组、TIMP-1组和CTGF＋TIMP-1组转染效率分别为10±2%、9±1%、8±2%和10±1%,均低于Com组的15±2%（P〈0.05）.结论成功构建靶向大鼠CTGF和TIMP-1最有效的RNA干扰靶位的双重RNA干扰表达质粒,能转染至肝星状细胞,并且psiRNA-GFP-Com转染效率最高.     

TROP2 shRNA真核表达载体转染胃癌BGC-823细胞的沉默作用

目的:构建TROP2特异性短发夹环RNA(shRNA)真核表达载体, 抑制人胃癌BGC-823细胞TROP2基因的表达.方法:构建TROP2短发夹环RNA, 产生重组质粒转染胃癌BGC-823细胞, 转染24 h后用G418(浓度400 mg/L)筛选, 待细胞稳定后收集, 分别命名为W组(未处理组), HK组(随机阴性对照质粒组), KB组(空质粒组), T1组, T2组, T3组. 并运用实时荧光定量PCR和Western blot检测TROP2的表达.结果:TROP2特异性shRNA片段被成功克隆进pGensil1.1质粒中, 重组质粒shRNA编码序列与设计片断的序列完全一致. 与未转染细胞组、随机阴性对照组、空质粒组相比, 转染shRNA重组质粒的人胃癌BGC-823细胞TROP2表达在mRNA和蛋白水平都受到抑制.与T1、T2组相比, T3组对TROP2 mRNA和蛋白抑制作用最明显, 差异具统计学意义(8.79±0.23 vs 9.54±0.20, 9.57±0.23; 3.66±0.11vs 6.46±0.36, 9.31±0.11, 均P<0.05).结论:成功构建了针对TROP2 的特异性shRNA真核表达载体并抑制了TROP2的表达,为进一步研究其基因功能打下了基础.     

人白介素-10基因转染对大鼠脑缺血再灌注损伤半影区炎性因子基因和蛋白表达的影响

目的 观察人白介素(IL)-10基因转染对大鼠局灶脑缺血再灌注损伤半影区肿瘤坏死因子-α(TNF-α)和白介素-1β(IL-1β)基因和蛋白表达的影响. 方法 建立大脑中动脉栓塞(MCAO)模型,采用立体定向脑室内注射的方式进行转染,逆转录-聚合酶链式反应(RT-PCR)和酶联免疫吸附实验(ELISA)检测其转染效果,氯化三苯四氮唑(TTC)染色测定脑梗死体积,荧光实时定量PCR检测半影区TNF-α和IL-1β基因表达情况,ELISA法检测半影区TNF-α和IL-1β蛋白的含量.结果 正常对照组、缺血对照组、空质粒组和IL-10基因转染组半影区TNF-α蛋白含量分别为(0.66±0.04)、(1.16±0.26)、(1.15±0.26)ng/g和(0.84±0.05)ng/g,IL-1β蛋白含量分别为(0.37±0.05)、(1.25±0.39)、(1.21±0.58)ng/g和(0.62±0.05)ng/g.与正常对照组比较,其余各组TNF-α和IL-1β蛋白含量明显升高(P＜0.01),而IL-10基因转染组TNF-α和IL一1β含量则较缺血对照组和空质粒组显著降低(P＜0.01);正常对照组,缺血对照组、空质粒组和IL-10基因转染组半影区TNF-αmRNA的表达量分别为1.00±0.53、9.42±1.83、9.69±1.96和3.53±1.09;IL-1βmRNA的表达量分别为1.00±0.51、27.81±4.84、23.96±4.90和13.55±4.45.与正常对照组比较,其余各组TNF-α和IL-1βmRNA表达量明显升高(P＜0.01),而IL-10基因转染组TNF-α和IL-1βmRNA表达量则较缺血对照组和空质粒组显著降低(P＜0.01). 结论 人IL-10基因转染后能抑制大鼠局灶脑缺血再灌注损伤半影区TNF-α和IL-1β基因和蛋白的表达,可能是其发挥缺血脑保护作用的机制之一.     

靶向mcl-l基因的shRNA真核表达质粒的构建与筛选

目的: 构建靶向髓细胞白血病基因-1(myeloid cell leukemia-1,mcl-1)的shRNA的真核表达质粒,并筛选出沉默mcl-1基因效果最明显的shRNA表达质粒.方法: 设计3对针对mcl-1基因不同位点的shRNA片段,构建携带此shRNAfi片段的真核表达质粒(shRNAl-3)并行酶切鉴定和测序分析.然后通过脂质体将重组质粒转染到肝癌细胞株HepG2中,48 h后测定转染率,并分别采用RT-PCR及Western blot检测mcl-1 mRNA和蛋白表达情况.结果: 重组质粒经酶切鉴定与测序证实构建成功.质粒在HepG2细胞中的转染率约为64%.shRNAl-3导入HepG2细胞48 h后.mcl-1,mRNA水平和蛋白水平均明显低于空白对照组和阴性对照组(0.61±0.02,0.56±0.02,0.46±0.01 vs 0.97±0.01,0.95±0.00;0.53±0.01.0.48±0.03,0_36±0.01vs0.90±0.03.0.88±0.01,均P<0.01).与shRNAl和shRNA2相比,shRNA3对mcl-1 mRNA和蛋白的抑制作用均最强(52.6%VS 36.3%,42.9%:63.2%vs41.5%,49.6%,均P<0.01).结论: 成功构建并筛选出的靶向mcl-1的shRNA真核表达质粒对肝癌细胞HepG2内的mcl-1表达具有明显抑制作用.     

重组结缔组织生长因子shRNA质粒的构建及其对肝星状细胞基因表达的影响

[目的]构建同时干扰大鼠结缔组织生长因子(CTGF)2个不同基因位点的shRNA质粒,并将其转染肝星状细胞(HSC),研究其对CTGF基因表达的影响。[方法]针对大鼠CTGF mRNA靶向序列设计并合成2对DNA模版序列,用PCR的方法将2条CTGF靶向特异性的shRNA分别链接到质粒pGenesil1.2载体的U6启动子和H1启动子。将构建的干扰质粒以阳离子脂质体法转染HSC-T6细胞,应用RT-PCR及Western Blot检测CTGF的表达。[结果]成功构建CTGF shRNA重组质粒;通过RT-PCR和Western Blot分析发现干扰质粒组的CTGF mRNA与蛋白表达水平明显下降(P0.05)。[结论]重组CTGF shRNA能有效抑制HSC中CTGF的表达。     

环磷酸腺苷反应元件结合蛋白-1对肝星状细胞转化生长因子β3的mRNA表达及启动子活性的影响

目的 探讨大鼠肝星状细胞(HSC)中,环磷酸腺苷(cAMP)反应元件结合蛋白-1(CREB-1)对转化生长因子β3 (TGFβ3)的mRNA表达及启动子活性的影响. 方法 将HSC分为CREB-1表达质粒转染组(C质粒组)、siRNA-CREB-1转染组(S质粒组)、阴性对照质粒组(N质粒组)、Forskolin处理组(FSK组)、H-89处理组(H-89组)及空白对照组,并根据加或不加入外源性TGFβ3重组蛋白将以上各组再分为(TGFβ3+)组和(TGFβ3-)组,实时荧光定量PCR法检测TGFβ3 mRNA的表达.上述各组共转染PGL3-basic-TGFβ3P (W质粒)或PGL3-basic-TGFβ3P-mCRE(M质粒),以pRL-SV40为空白对照,荧光素酶报告基因分析法检测各组TGFβ3启动子活性.双侧t检验进行组间数据比较. 结果 TGFβ3 mRNA表达结果显示,与N质粒(TGFβ3-)组比较,S质粒(TGFβ3-)组mRNA相对表达量降低至0.69±0.15(t=3.702,P＜0.05);与空白对照(TGFβ3-)组比较,H-89 (TGFβ3-)组降低至0.57±0.08(t=9.490,P＜0.05);N质粒(TGF β 3+)组与N质粒(TGFβ3-)组、S质粒(TGFβ3+)组与S质粒(TGFβ3-)组、空白对照(TGFβ3+)组与空白对照(TGFβ3-)组、H-89 (TGFβ3+)组与H-89 (TGFβ3-)组分别比较,差异均有统计学意义(t值分别为-7.404、-3.480、-2.831和7.875,P值均＜0.05).荧光素酶报告基因分析结果显示,S+W质粒组、N+W质粒组、C+W质粒组的TGFβ3启动子活性分别为0.062±0.013、0.122±0.011、0.165±0.016,C+W质粒组TGFβ3活性较N+W质粒组组明显升高(t=-3.823,P＜ 0.05),S+W质粒组较N+W质粒组明显降低(t=5.853,P＜0.01);H-89+W质粒组、空白对照+W质粒组、FSK+W质粒组TGFβ3启动子活性分别为0.154±0.010、0.188±0.016、0.276±0.031,FSK+W质粒组的TGFβ3启动子活性较空白对照+W质粒组明显升高(t=-4.419,P＜0.05),H-89+W质粒组的TGFβ3启动子活性较空白对照+W质粒组明显降低(t=-3.115,P＜0.05). 结论 增加HSC内CREB-1表达或提高CREB-1磷酸化水平可上调TGFβ3 mRNA表达及其启动子活性;CRE位点是TGFβ3启动子的关键位点,封闭该位点后,TGFβ3启动子活性明显降低.外源性TGFβ3可上调HSC中内源性TGFβ3 mRNA的表达.     

戒烟对吸烟大鼠气道上皮细胞核因子κB、基质金属蛋白酶9及金属蛋白酶组织抑制物1表达的影响

目的 通过研究吸烟及戒烟大鼠气道上皮细胞核因子κB(NF-κB)、细胞基质金属蛋白酶9(MMP-9)及细胞金属蛋白酶组织抑制物1(TIMP-1)mRNA及蛋白质的表达水平,探讨吸烟及戒烟对慢性阻塞性肺疾病气道炎症和气道重塑的影响.方法 雄性Wistar大鼠24只,随机分为对照组、吸烟组和戒烟组,每组8只.分别采用原位杂交和免疫组织化学的方法检测各组大鼠气道上皮细胞中NF-κB、MMP-9及TIMP-1 mRNA及蛋白的表达水平.结果 ①与对照组(0.29±0.06,0.29±0.06)相比,吸烟组(0.45±0.04,0.41±0.03)、戒烟组(0.40±0.05,0.37±0.03)NF-κB mRNA和蛋白表达水平均增高(P值均＜0.05);与吸烟组相比,戒烟组NF-κB mRNA和蛋白表达水平降低(P值均＜0.05).②与对照组(0.30±0.06,0.30±0.06)相比,吸烟组(0.52±0.03,0.51±0.07)、戒烟组(0.38±0.03,0.33±0.02)MMP-9 mRNA和蛋白表达水平均增高(P值均＜0.05);与吸烟组相比,戒烟组MMP-9mRNA和蛋白表达水平均降低(P值均＜0.05).③与对照组(0.26±0.04,0.26±0.04)相比,吸烟组(0.49±0.05,0.37±0.03)、戒烟组(0.42±0.04,0.35±0.03)TIMP-1 mRNA和蛋白表达水平均增高(P值均＜0.05);与吸烟组相比,戒烟组TIMP-1 mRNA和蛋白表达水平降低(P值均＜0.05).④与对照组(1.00±0.02,1.00±0.02)相比,吸烟组(1.07±0.14,l.37±0.19)MMP-9/TIMP-1 mRNA和蛋白表达值大于1(P值均＜0.05),而戒烟组(0.92±0.13,0.94±0.10)MMP-9/TIMP-1 mRNA和蛋白表达值小于1(P值均＜0.05).⑤各组NF-κB和MMP-9的mRNA及蛋白的表达呈正相关(r值分别为0.87和0.66,P值均＜0.05).结论 吸烟大鼠气道上皮细胞NF-κB、MMP-9和TIMP-1 m-RNA及蛋白的表达水平升高,并且MMP-9/TIMP-1大于1,戒烟后NF-κB、MMP-9和TIMP-1的表达有所下降,且MMP-9/TIMP-1小于1,提示吸烟可以引起气道上皮的炎症和重塑,戒烟可以减轻气道炎症和重塑.     

2型糖尿病患者基质金属蛋白酶组织抑制因子-1的表达及与空腹血糖的相关性

目的探讨2型糖尿病患者基质金属蛋白酶组织抑制因子(TIMP)-1的表达及与空腹血糖的相关性。方法收集该院内分泌科2010年1月至2013年12月住院的2型糖尿病患者21例作为病例组,另选取体检正常者21例作为对照组,利用双抗体夹心ELISA法测定血浆TIMP-1水平,AU640生化分析仪检测空腹血糖水平。结果病例组总TIMP-1表达为(4.125±1.210)ng/ml,明显高于对照组(3.214±0.125)ng/ml(P<0.05),并且病例组病程5¹0年、1010年、10¹5年、1515年、15²0年TIMP-1的表达水平均高于对照组(P<0.05);病例组中24 h尿蛋白正常排泄组的总TIMP-1表达为(3.544±1.225)ng/ml,低于异常排泄组的(5.128±1.326)ng/ml(P<0.05);病例组中TIMP-1的表达随着病程逐渐升高(F=9.987,P=0.000);病例组空腹血糖平均值为(8.125±2.458)mmol/L,与血浆TIMP-1之间散点图呈负相关趋势,pearson相关性分析呈现明显的负相关(r=-0.876,P=0.000)。结论 2型糖尿病患者血浆TIMP-1的表达水平比正常者高,并且随着病程逐渐增高。与空腹血糖之间呈现明显负相关关系。     

高表达谷胱甘肽过氧化物酶1对阿尔茨海默病细胞模型的作用

目的 将谷胱甘肽过氧化物酶1 (GPX1)重组质粒转染肾上腺嗜铬细胞瘤(PC12)细胞,使其在细胞内高表达,探讨GPX1清除自由基、抗氧化应激的细胞保护作用。 方法 将GPX1重组质粒、pLNCX空载体质粒转染PC12细胞,用新霉素(G418)筛选稳定表达GPX1的PC12细胞,以不同β-淀粉样蛋白(Aβ)25-35浓度诱导PC12细胞48 h,确定最佳Aβ25-35浓度,构建理想阿尔茨海默病(AD)细胞模型。以最佳Aβ25-35浓度分别诱导转染GPX1重组质粒组、转染pLNCX空载体质粒组和正常PC12细胞组48 h,比色法比较其吸光度(A)值。 结果 用G418筛选出了稳定高表达GPX1的细胞克隆。与无Aβ25-35的空白对照组比较,20 μmol/LAβ25-35可使PC12细胞的抑制率显著升高,达24.7％,差异有统计学意义(P＜0.01),确定Aβ25-35的最佳诱导浓度为20 μmol/L。最佳Aβ25-35诱导浓度诱导各细胞组48h后,与转染pLNCX空载体质粒细胞组和正常PC12细胞组比较,转染GPX1重组质粒细胞组A值明显升高,分别为[（0.53±0.02）与(0.44±0.02),（0.53±0.02）与(0.39±0.07),均P＜0.01]结论转染GPX1重组质粒可增强细胞清除自由基的能力,逆转Aβ25-35所致的细胞生存率降低。     

姜黄素对肝纤维化大鼠CTGF及TIMP-1和NF-kB表达的影响

目的 观察姜黄索预防肝纤维化过程中肝脏组织中结缔组织生长因子(CTGF)、金属蛋白酶组织抑制剂-1(T1MP-1)、核因子-kB(NF-kB)表达的变化,探讨姜黄素预防肝纤维化的作用机制.方法 四氯化碳腹腔注射8周以建立大鼠肝纤维化模型.同时每只大鼠按每100g体重分别给予20mg、10 mg、5 mg姜黄素灌胃处理.3次/周,共8周;所有大鼠随机分为6组(正常组、肝纤维化模型组、高剂量姜黄素组、中剂量姜黄素组、低剂量姜黄素组和阳性对照组.8周后处死大鼠,留取肝脏组织,免疫组织化学方法 检测肝组织中CTGF、TLMP-1、NF-kB心的表达水平,进行图像分析并统计各组阳性表达率差别.结果 模型组大鼠肝组织中CTGF、TLMP-1、NF-KB大量表达.姜黄素可明显抑制上述因子的表达(P<0.01).结论 姜黄素预防肝纤维化作用可能与其抑制CTGF、TIMP-1、NF-kB的表达有关.     

肝炎、肝硬化、肝癌及胃癌患者血清MMP—1、TIMP—1以及MMP—1／TIMP—1复合物的检测

目的 检测血清基质金属蛋白酶－1（MMP－1）、组织金属蛋白酶抑制剂－1（TIMP－1）及两者复合物（MMP－1／TIMP－1 com-plex）含量并评价其变化意义。方法 采用双抗体夹心式酶联免疫吸附法（ELISA）对10例健康对照、15例急性肝炎患者、15例慢性活动性肝炎患者;15例晚期肝硬化患者、15例肝癌手术患者、15例晚期肝癌患者以及10例胃癌入院手术患者进行检测。结果 与健康对照组相比,慢性活动对肝炎、晚期肝硬化以及晚期肝癌患者血清TIMP－1水平显著提高;慢性活动性肝炎及肝癌手术患者组血清MMP－1及MMP－1／TIMP－1复合物水平显著下降;急性肝炎及胃癌手术患者血清MMP－1、TIMP－1及MMP－1／TIMP－1复合物含量无显著变化。结论 在慢性活动性肝炎、晚期肝硬化以及肝癌患者存在严重的MMP－1和TIMP－1的失平衡,这种失平衡是这些患者肝脏细胞外基质净沉积的重要原因。MMP－1和TIMP－1在急性肝炎和胃癌患者血清含量总体变化不显著。     

Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls

BACKGROUND: Excess tissue matrix accumulates in systemic sclerosis (SSc), accounting for both visceral and dermal fibrosis. It is suggested that decreased serum levels of matrix metalloproteinases (MMPs) or increased levels of tissue inhibitors of matrix metalloproteinases (TIMPs) may account for this matrix accumulation. OBJECTIVE: To measure serum levels of tissue inhibitors of metalloproteinases, TIMP-1, TIMP-2, and collagenase-1 (MMP-1), in patients with diffuse cutaneous systemic sclerosis (dcSSc), limited cutaneous systemic sclerosis (lcSSc), primary Raynaud's phenomenon (RP), and in normal controls. METHODS: Serum samples from patients with dcSSc (n=83), lcSSc (n=87), RP (n=80), and normal controls (n=98) were analysed using enzyme linked immunosorbent assays (ELISAs) for total TIMP-1, TIMP-2, and MMP-1. Results from each assay were analysed by the Kruskal-Wallis test. Dunn's multiple comparison post-test was then applied between groups. RESULTS: TIMP-1 levels were significantly raised in dcSSc and lcSSc groups compared with the RP group and normal controls (p<0.01 to p<0.001). In the dcSSc group, TIMP-1 levels were significantly higher in early disease (<2 years) than in late stage disease (>4 years) (p<0.05). This was not found for the lcSSc group. Serum TIMP-2 and MMP-1 levels in dcSSc and lcSSc did not differ significantly from those in normal controls. Increased levels of TIMPs were not convincingly associated with organ disease. No assay result correlated with autoantibody status (anti-topoisomerase 1 (anti-Scl-70), anticentromere antibody, or anti-RNA polymerase). No significant differences in serum TIMP-1, TIMP-2, or MMP-1 levels were shown in the RP group compared with normal controls. CONCLUSIONS: Raised TIMP-1 levels in the SSc groups support the hypothesis that matrix accumulation occurs in SSc at least in part owing to decreased degradation. Moreover, the variation in TIMP-1 levels between the early and late disease stages of dcSSc seems to reflect the early progressive course of dermal fibrosis seen clinically. The expected reduction in serum MMP-1 levels in the SSc groups was not found. This suggests that tissue matrix accumulation is due to increased inhibitors rather than to decreased MMPs.     

Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma

OBJECTIVES: The influence of matrix-tumour interactions in Hodgkin's lymphoma is poorly characterised, although a large part of the tumour often consists of reactive tissue. The aim of the present study was to assess the clinicopathological role of two main inhibitors of matrix metalloproteinases, TIMP-1 and TIMP-2, in Hodgkin's lymphoma. MATERIALS AND METHODS: The TIMP-1 and TIMP-2 protein expressions were studied from paraffin-embedded tumour sections of 68 patients with Hodgkin's lymphoma by using immunostaining with TIMP-1 and TIMP-2-specific antibodies. The results of the stainings were compared with the clinicopathological disease characteristics. RESULTS: A total of 33.3% of the tumour tissue sections expressed TIMP-1 and 46.8% expressed TIMP-2. The expression of the TIMP-1 protein was found to be strongly associated with the nodular sclerosis subtype (P = 0.015) and the existence of a bulky tumour (P = 0.004) in Hodgkin's lymphoma. The expression of the TIMP-2 protein, on the other hand, correlated with the occurrence of B symptoms (P = 0.032). CONCLUSIONS: These results provide the first clinical evidence suggesting that TIMP-1 could promote growth of Hodgkin's lymphoma, and may be linked to connective tissue turnover in the nodular sclerosis subtype. However, TIMP-2 is shown to correlate with systemic symptoms.     

MMP-1、TIMP-1和TNF-α在溃疡性结肠炎中表达的意义

目的研究基质金属蛋白酶-1（MMP-1）及其抑制剂-1（TIMP-1）、肿瘤坏死因子-α（TNF-α）在溃疡性结肠炎（UC）结肠黏膜不同区域以及不同病情中的表达,探讨它们在UC发生发展中的作用和I临床意义。方法收集UC不同区域的结肠黏膜组织,分为轻、中、重三组。采用逆转录-聚合酶链反应（RT—PCR）及免疫组化检测三种因子的表达。结果MMP—1、TIMP—1、TNF-α在溃疡区的表达高于非溃疡区（P〈0．05）。MMP-1、TNF-α及TIMP-1在重型中的表达高于轻型（P〈0．05）。MMP-1／TIMP-1、TNF-α与病情严重程度相关（P〈0．05）。结论结肠黏膜中TNF-α表达升高,引起黏膜组织免疫失调,可能引起MMP-1与TIMP-1表达失衡,在UC的发生发展中起重要作用。MMP-1／TIMP-1和TNF-α可作为评价UC病情的指标。     

Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis

AIM: To investigate the location and expression of TIMP-1 and TIMP-2 in the liver of normal and experimental hepatic fibrosis in rats. METHODS: The rat models of experimental immunity hepatic fibrosis (n=20) were prepared by the means of immunologic attacking with human serum albumin (HSA),and normal rats (n=10) served as control group. Both immunohistochemistry and in situ hybridization methods were respectively used to detect the TIMP-1 and TIMP-2 mRNA and related antigens in liver. The liver tissue was detected to find out the gene expression of TIMP-1 and TIMP-2 with RT-PCR. RESULTS: The TIMP-1 and TIMP-2 related antigens in livers of experimental group were expressed in myofibroblasts and fibroblasts (TIMP-1: 482&#177;65 vs 60&#177;20; TIMP-2:336&#177;48 vs 50&#177;19, P&lt;0.001). This was the most obvious in portal area and fibrous septum. The positive signals were located in cytoplasm, not in nucleus. Such distribution and location were confirmed bysitu hybridization (TIMP-1/β-actin: 1.86&#177;0.47 vs 0.36&#177;0.08; TIMP-2/β-actin: 1.06&#177;0.22 vs 0.36&#177;0.08,P&lt;0.001). The expression of TIMP-1 and TIMP-2 was seen in the liver of normal rats, but the expression level was very low. However, the expression of TIMP-1 and TIMP-2 in the liver of experimental group was obviously high. CONCLUSION: In the process of hepatic fibrosis, fibroblasts and myofibroblasts are the major cells that express TIMPs.The more serious the hepatic fibrosis is in the injured liver,the higher the level of TIMP-1 and TIMP-2 gene expression.     

TIMP-1和TIMP-2在原发性肝癌生长、浸润及转移中的作用

目的：了解基质金属蛋白酶组织抑制因子-1(tissue inhibitou of metalloproteinase-1，TIMP-1)和基质金属蛋白酶组织抑制因子-2(TIMP-2)mRNA及相关抗原在肝癌组织中的定位和表达状态，探讨TIMP-1和TIMP-2在肝癌组织生长、浸润及转移中所起的作用。方法：以TIMP-1和TIMP-2探针及单克隆抗体（McAb）为试剂，采用原位杂交技术及免疫组织化学法检测原发性肝癌、肝高分化腺癌的肝组织中TIMP-1和TIMP-2mRNA及相关抗原的表达，并与10例正常肝组织做对照。结果：20例原发性肝癌患者的肝组织中TIMP-1和TIMP-1mRNA及相关抗原表达的阳性率为90%;9例肝高分化腺癌的腺癌组织中无TIMP-1和TIMP-2mRNA及相关抗原的表达；10例正常肝组织中TIMP-1和TIMP-2mRNA及相关抗原表达均为阴性；TIMP-1和TIMP-2mRNA及相关抗原阳性信号呈现为棕黄色颗粒状，分布在肝细胞浆内，未见细胞核着色；无论是原发性肝癌癌组织还是癌周组织中,TIMP-1的表达强于TIMP-2的表达，癌周组织中TIMP-1和TIMP-2mRNA和相关抗原的表达与肝组织病理改变相关，即肝硬化者表达强，慢性肝炎者表达弱，正常肝组织无表达。结论：原发性肝癌的癌组织中存在TIMP-1和TIMP-2mRNA及相关抗原的表达，其表达强度可能与原发性肝癌的分型有关，它可能通过抑制MMP的活性使ECM降解减少从而阻止癌细胞通过基底膜移出而抑制肝癌细胞向周围浸润及转移。     

MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis

OBJECTIVE: Rheumatoid arthritis (RA) and psoriatic arthritis (PA) are both chronic rheumatic inflammatory diseases characterized by disruption of the extra-cellular matrix (ECM) protein of the cartilage, likely induced by proteolytic enzymes such as matrix metalloproteases (MMPs). The goal of this study was to quantify the expression of MMPs such as MMP-2 and MMP-9, and their physiological tissue inhibitors TIMP-2 and TIMP-1, respectively, in serum and synovial fluid. METHODS: Serum and synovial fluid from 24 RA patients and 17 PA patients were studied to determine the levels of MMP-2 and MMP-9 proteolytic activity using a modified gelatin zymography procedure. TIMP-1 and TIMP-2 were measured by a commercially available ELISA kit. RESULTS: Our results show that MMP-2 was detected in the latent form only, while MMP-9 was present in latent and active form. Both gelatinases were more concentrated in synovial fluid than in serum, and TIMP-1 and TIMP-2 concentrations were also more elevated in synovial fluid than in serum. CONCLUSIONS: To investigate the remodelling of cartilage ECM proteins, the evaluation of synovial fluid concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 is more reliable than that determined in serum. In view of these data, MMPs inhibitors might represent a possible target for new therapies delivered directly in the joint space.     

Local expressions of TGF-beta1, TGF-beta1RI, CTGF, and Smad-7 in Helicobacter pylori-associated gastritis

OBJECTIVE: Transforming growth-factor (TGF)-beta1 and Smad-7 play important roles in Helicobacter pylori (H. pylori)-associated gastritis. Connective tissue growth factor (CTGF) can facilitate the TGF-beta/Smad signaling by switching off Smad-7. The purpose of this study was to examine the in situ expressions of these cytokines in the gastric antrum with or without H. pylori infection. MATERIAL AND METHODS: Antral specimens from 166 patients (96 M, 70 F, median age 52 years, range 26 to 76 years) were used in this study. H. pylori infection status was determined by histological examination and (UBT) [13C]-urea breath test. Degrees of severity and activity of chronic gastritis were scored for all specimens. Immunohistochemistry was used to demonstrate local expressions of TGF-beta1, TGF-beta1 type 1 receptor (TGF-beta1RI), Smad-7, and CTGF in the gastric antrum. RESULTS: The results demonstrated that mononuclear cells (MNCs) in lamina propria were the major source of these cytokines. The number of MNCs stained with TGF-beta1, TGF-beta1RI, CTGF, and Smad-7 was significantly higher in H. pylori-positive patients than in H. pylori-negative patients. Furthermore, there was a positive correlation between these cytokine-producing MNCs and the severity of chronic gastritis. CONCLUSIONS: H. pylori infection is associated with increased expression of TGF-beta1, TGF-beta1RI, Smad-7, and CTGF in the gastric antrum. Our results also suggest that the feed-back loop consisting of TGF-beta1, Smad-7, and CTGF may play an important role in the pathogenesis of H. pylori-associated gastritis.     

Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis

Recent evidence suggests that matrix metalloproteinases (MMPs) were involved with many kinds of kidney diseases. We investigated the roles of MMPs and its tissue inhibitors TIMPs in patients with lupus nephritis (LN). A total of 44 systemic lupus erythematosus patients and 31 healthy subjects were enrolled. The levels of total MMP-2, 9 (tMMP-2, tMMP-9) along with TIMP-1, 2 were measured in serum by ELISA. Serum tMMP-2, tMMP-9 was higher in LN patients than those non-LN patients and healthy controls. Serum tMMP-2 in patients without LN was higher than in healthy controls. TIMP-2 was higher in LN patients than healthy controls, and no significant difference in TIMP-2 was observed between LN and non-LN patients. TIMP-1 levels among LN, non-LN patients and healthy controls were comparable. The ratio of tMMP-9 to TIMP-1 in LN patients was higher than non-LN patients and healthy controls and no difference in ratio of tMMP-9 to TIMP-1 between non-LN patients and healthy subjects was observed. A negative correlation between the ratio of tMMP-9 to TIMP-1 in lupus patients and the titers of anti-dsDNA was found; whereas, no correlation between the ratio of tMMP-9 to TIMP-1 and the concentration of C3 as well 24 h urine protein was observed in LN patients. We suggest imbalance between tMMP-9 and TIMP-1 may contribute to the pathogenesis of LN. Measurement of MMPs and TIMPs may be helpful in the early identification of lupus patients with LN and may help gauge the response to treatment in patients with active LN undergoing treatment.